ARID5B

ARID5B

A gene on chromosome 10q21.2 that encodes a transcription coactivator, playing a key role in adipogenesis and liver development by forming a complex with phosphorylated PHF2. The PHF2-ARID5B complex targets promoters and activates transcription of target genes. It acts as a coactivator of HNF4A in liver and is required for adipogenesis, regulating triglyceride metabolism in adipocytes by regulating expression of adipogenic genes.
References in periodicals archive ?
Modulator recognition factor-2 (MRF2) is a member of the AT-rich interaction domain (ARID) family of transcription factors (also known as ARID5B or Desrt ).
Normally, a protein called ARID5B squats on the enhancer and prevents it from dialing up activity of the fat-determining genes.
Caption: Fat Switch Energy-burning beige fat is made when a protein called ARID5B prevents a bit of DNA that acts as an enhancer from turning on two faraway genes (IRX3 and IRX5).
That is not to say that chromatin-remodeling genes and genes of the ubiquitin ligase complex are not also perturbed in the endometrioid subtype; indeed, a number of chromatin-remodeling genes, such as ARID1A, ARID5B, CTCF, and CHD4, are also causal or candidate driver genes in molecular subgroups dominated by endometrioid endometrial tumors (Table 1).
of Gene subgroup SMGs symbol Hypermutated/ 21 PTEN microsatellite- PIK3CA unstable PIK3R1 ARID1A RPL22 KRAS ZFHX3 ARID5B CTCF CTNNB1 ATR GIGYF2 CSDE1 FGFR2 CCND1 LIMCH1 RBMX NKAP HIST1H2BD TNFAIP6 MIR1277 Copy number low/ 16 PTEN microsatellite- PIK3CA stable CTNNB1 ARID1A PIK3R1 CTCF KRAS FGFR2 CHD4 SPOP CSMD3 (b) SOX17 SGK1 BCOR MECOM METTL14 Copy number high 8 TP53 (serous-like) PIK3CA FBXW7 PPP2R1A PIK3R1 CHD4 PTEN CSMD3 (b) Molecular Gene name Somatic-mutation subgroup frequency Hypermutated/ Phosphatase and tensin homolog 87.
Novel mutations also were discovered in the SWI/SNF chromatin remodeling complex gene ARID5B.
Jude Pharmaceutical Sciences chair and the paper's senior author, estimated that individuals who inherited variations in the genes, known as ARID5B and IKZF1, were almost twice as likely to develop ALL.
The inherited variations in ARID5B might also influence patient response to chemotherapy, particularly to the drug methotrexate.
These findings may identify a new marker that could be used to help decide on doses of methotrexate in patients with varying ARID5B status.